SLC5A2 and heart failure: <b>Background</b>: Finerenone and sodium-glucose cotransporter-2 inhibitors provide cardiovascular and renal benefits in patients with chronic kidney disease (CKD) and heart failure (HF), but real-world comparative evidence is limited.